Chest-Worn Patch Measures SpO₂; Integrates ECG, Temperature, and Other Vital Signs; Blood Pressure Monitoring Approval Expected in Q4

Digital healthcare company Meju has demonstrated its ability to measure blood oxygen saturation (SpO₂) using a chest-worn wearable device. Moving beyond ECG-centered monitoring, the company is expanding into an integrated platform for continuous monitoring of multiple vital signs.
 

On the 14th, Meju announced that it had received MFDS approval for a modification to its next-generation wearable patient monitoring device, HiCardi M350, adding SpO₂ measurement functionality.
 

HiCardi M350 had previously received MFDS manufacturing approval for multichannel electrocardiogram (ECG), respiratory rate, and continuous body-temperature monitoring. With the latest approval, the addition of SpO₂ monitoring expands the device into a multiparameter patient monitor that enables real-time, integrated management of four key vital signs with a single patch.
 

SpO₂ is generally measured using optical sensors attached to the finger or earlobe. However, the need for separate wired cables can restrict patient movement and reduce wearing comfort. Obtaining reliable optical signals from the chest is particularly challenging, as blood-flow signals are weaker than in peripheral areas and more vulnerable to motion-related noise.
 

Meju applied proprietary signal-processing technology tailored to chest signals, along with reflective photoplethysmography (PPG), and demonstrated performance in a clinical trial for regulatory approval. The technology enables stable monitoring without a finger sensor or cable connection, making it well suited to mobile remote patient-monitoring settings within hospitals.